Analyst Price Targets — ESPR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 1, 2026 7:20 pm | — | Jefferies | $3.28 | $3.11 | TheFly | Esperion downgraded to Hold from Buy at Jefferies |
| May 1, 2026 6:01 pm | — | Piper Sandler | $3.16 | $3.11 | TheFly | Esperion downgraded to Neutral from Overweight at Piper Sandler |
| May 1, 2026 1:38 pm | — | H.C. Wainwright | $3.16 | $3.11 | TheFly | Esperion downgraded to Neutral from Buy at H.C. Wainwright |
| May 1, 2026 12:44 pm | — | Cantor Fitzgerald | $3.16 | $2.00 | TheFly | Esperion downgraded to Neutral from Overweight at Cantor Fitzgerald |
| November 24, 2025 10:30 pm | — | Piper Sandler | $9.00 | $3.17 | TheFly | Esperion initiated with an Overweight at Piper Sandler |
| September 25, 2025 6:15 pm | Kristen Kluska | Cantor Fitzgerald | $9.00 | $2.56 | TheFly | Esperion price target raised to $9 from $7 at Cantor Fitzgerald |
| December 17, 2024 11:36 am | Kristen Kluska | Cantor Fitzgerald | $8.00 | $3.04 | TheFly | Esperion initiated with an Overweight at Cantor Fitzgerald |
| May 4, 2022 12:00 am | Serge Belanger | Needham | $12.00 | $6.53 | TipRanks Contributor | Esperion Therapeutics Rises on Upbeat Q1 Results |
| May 4, 2021 12:00 am | Derek Archila | Wells Fargo | $20.00 | $25.59 | Benzinga | Esperion Stock Plummets On Wider Than Expected Q1 Earnings Loss; Analysts Move To Sidelines |
Latest News for ESPR
Stockholders of Esperion Therapeutics NASDAQ: ESPR approved the company's merger agreement with Essence Parent and Essence MergerCo at a special meeting held virtually on July 8, 2026, according to remarks delivered during the meeting.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in…
– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years – – A Secondary Analysis of CLEAR Outcomes Reports on Patient Factors Associated With 30% or Greater Reduction in LDL-C in Statin Intolerant Adults – ANN ARBOR, Mich., May 26, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from a Phase 2 study of bempedoic acid in children, along with an…
ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.
Esperion shares jump nearly 44% in a month. The primary catalyst was Archimed's agreement to acquire the company in a deal valued at up to $1.1 billion, including milestone payments.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ESPR.
U.S. House Trading
No House trades found for ESPR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.